#Merz Therapeutics

16 Oct 2026

Merz Wraps Enrollment in Xeomin Migraine Trials

Merz Therapeutics finished enrolling roughly 1,800 patients in two Phase III studies testing Xeomin for migraine prevention, ahead of schedule.

Read more